相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis
Jienchi Dorward et al.
LANCET HIV (2021)
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Shahin Lockman et al.
LANCET (2021)
Assessing the capacity and findings of routine programmatic data in Kenya to guide decision-making around contraceptives and antiretroviral therapy
Beth A. Tippett Barr
BMC MEDICINE (2021)
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
Andrew N. Phillips et al.
LANCET HIV (2020)
Dolutegravir and neural tube defects: a new insight
Laurent Chouchana et al.
LANCET INFECTIOUS DISEASES (2020)
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial
Kenneth Kintu et al.
LANCET HIV (2020)
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Willem D F Venter et al.
Lancet HIV (2020)
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Alexandra Calmy et al.
Lancet HIV (2020)
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda
Yussif Alhassan et al.
BMC PUBLIC HEALTH (2020)
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Mark J. Siedner et al.
NATURE COMMUNICATIONS (2020)
Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
Anthony Hauser et al.
PLOS MEDICINE (2020)
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study
Gerson Fernando Mendes Pereira et al.
Lancet HIV (2020)
Weight gain during pregnancy among women initiating dolutegravir in Botswana
Ellen C. Caniglia et al.
ECLINICALMEDICINE (2020)
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
Steve Kanters et al.
ECLINICALMEDICINE (2020)
Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential
Caitlin M. Dugdale et al.
ANNALS OF INTERNAL MEDICINE (2019)
Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study
D. Money et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2019)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Rebecca Zash et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dolutegravir Use at Conception - Additional Surveillance Data from Botswana
Mmakgomo M. Raesima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects
Lynne M. Mofenson et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2019)
Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres
Agnes Kant et al.
DRUG SAFETY (2019)
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
Andrew N. Phillips et al.
LANCET HIV (2019)
The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
Marco Vitoria et al.
AIDS (2018)
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception
Rebecca Zash et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sex Differences in HIV Prevalence Persist over Time: Evidence from 18 Countries in Sub-Saharan Africa
Hanne K. Hegdahl et al.
PLOS ONE (2016)
Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025
Aastha Gupta et al.
PLOS ONE (2016)
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
Nathan Ford et al.
AIDS (2014)
Myelomeningocele in a child with intrauterine exposure to efavirenz
C Fundarò et al.
AIDS (2002)
分享论文
